Biotech Growth Trust plc (The) (BIOG) Ordinary 25p

Sell:1,180.00pBuy:1,185.00pNo change

FTSE All Share:0.44%
Market closed |
Prices delayed by at least 15 minutes
Sell:1,180.00p
Buy:1,185.00p
Change:No change
Market closed |
Prices delayed by at least 15 minutes
Sell:1,180.00p
Buy:1,185.00p
Change:No change
Market closed |
Prices delayed by at least 15 minutes

Trust Information

About this company

The Biotech Growth Trust PLC is a United Kingdom-based externally managed investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company invests more than 10%, in aggregate, of the value of its gross assets in other closed-end investment companies (including investment trusts) listed on the London Stock Exchange. The Company invests more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. Its portfolio of investments across various countries includes the Netherlands, the United States of America, Canada, and China. The Company’s alternative investment fund manager is Frostrow Capital LLP.

Objective

The Company seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.

Costs

  • Ongoing charge1.20%
  • Annual management charge -
  • Performance feeYes

Fee structure

AIFM receives a periodic fee equal to 0.30% p.a. of the market capitalisation up to GBP500m, 0.20% above GBP 500m to GBP 1bn and 0.10% over GBP 1bn. The Investment Manager receives a fee equal to 0.65% p.a. of the net assets. The Agreement may be terminated with not less than 12 months notice.

Value Assessment

  • Value Assessment review date30 March 2025
  • Value Assessment next review date30 March 2026
  • Is Assessment of Value required under COLL?No
  • Outcome of COLL Assessment of Valuen/a
  • Outcome of PRIN Value Assessment or reviewProduct expected to provide fair value for reasonably foreseeable period
  • Other review related to value and or charges -
  • Further information-
Click to see more

Key facts

  • Currency
    GBX
  • Benchmark
    NASDAQ Biotechnology TR GBP
  • Shares in issue
    22.41m
  • Gross gearing
    9.00%
  • EPIC
    BIOG
  • ISIN
    GB0000385517
  • Domicile
    United Kingdom
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.